Latest technologies from Mount Sinai School of Medicinehttp://otbd.technologypublisher.comBe the first to know about the latest inventions and technologies available from Mount Sinai School of Medicineen-USFri, 01 Aug 2014 06:52:28 GMTSat, 22 Mar 2014 10:48:40 GMThttp://blogs.law.harvard.edu/tech/rsstechnology@mssm.eduCopyright 2014, Mount Sinai School of MedicineTreatment of Phelan-McDermid Syndrome and SHANK3 Mutationshttp://otbd.technologypublisher.com/technology/14802The SHANK3 family of proteins plays a critical role in the functioning of synapses. Within synapses, the SHANK3 proteins act as scaffolds that connect neurons and influences dendrite spine maturation.  Hence, the SHANK3 gene is essential to the development of the human nervous system.  Phelan-McDermid Syndrome (PMS)—also called 22q13 Deletion Syndrome (22q13DS)—is a rare genetic syndrome in which one copy of the q13 portion of chromosome 22 is either missing or otherwise mutated. There is overwhelming evidence that it is the loss of one copy of the SHANK3 gene in this region is responsible for...Sat, 22 Mar 2014 10:48:40 GMTtechnology@mssm.eduhttp://otbd.technologypublisher.com/technology/14802REGISTERED COPYRIGHT No. TX7-713-909 - Autism Mental Status Examinationhttp://otbd.technologypublisher.com/technology/12289Thu, 11 Apr 2013 07:09:18 GMTtechnology@mssm.eduhttp://otbd.technologypublisher.com/technology/12289Small Molecule-Mediated Directed Cardiomyocyte Differentiation of Human Pluripotent Stem Cellshttp://otbd.technologypublisher.com/technology/12267The ability to differentiate stem cells (human or pluripotent (iPS)) into cardiomyocytes offers not only valuable tools for research in cardiovascular development but potentially a path to cell therapy.  Current methods of differentiation into cardiomyocytes suffer from low yield and the hetergoneity in the derived cardiomyocytes.  In addition, inconsistencies in serum and other biomolecules and the high costs of growth factors prevent the current protocols from being scalable.   The research team at the Icahn School of Medicine at Mount Sinai led by Dr Roger Hajjar has devised a novel method ...Thu, 04 Apr 2013 08:35:50 GMTtechnology@mssm.eduhttp://otbd.technologypublisher.com/technology/12267SUMO1: Therapeutic Target for Heart Failurehttp://otbd.technologypublisher.com/technology/12264Thu, 04 Apr 2013 06:12:54 GMTtechnology@mssm.eduhttp://otbd.technologypublisher.com/technology/12264A Method To Isolate Pure Mitochondrial DNAhttp://otbd.technologypublisher.com/technology/12220Fri, 22 Mar 2013 08:56:25 GMTtechnology@mssm.eduhttp://otbd.technologypublisher.com/technology/12220Application of mGluR Antatonists for Psychiatric Disorders Caused or Worsened by Cyfip1 Variationshttp://otbd.technologypublisher.com/technology/12219Fri, 22 Mar 2013 08:53:07 GMTtechnology@mssm.eduhttp://otbd.technologypublisher.com/technology/12219Use of Acid Ceramidase For The Treatment of Lung Diseasehttp://otbd.technologypublisher.com/technology/11763Wed, 23 Jan 2013 06:16:01 GMTtechnology@mssm.eduhttp://otbd.technologypublisher.com/technology/11763Methods for Programming Differentiated Cells Into Hematopoietic Stem Cellshttp://otbd.technologypublisher.com/technology/11738Hematopioetic transplantation is the most common and successful example of stem cell therapy.  In patients with hematological disease, there continues to be a short supply of stem cells from bone marrow and umbilical cord blood because of the lack of sufficient number of immunologically compatible donors and the low number of hematopoietc stem cells (HSCs).  Direct programming of HSCs from differentiated cells from patients or suitable donors offers a method that overcomes existing limitations and provides an unlimited source of material for treatment.                  Professors Ihor Lemischk...Thu, 17 Jan 2013 05:09:26 GMTtechnology@mssm.eduhttp://otbd.technologypublisher.com/technology/11738Acid Ceramidase as a Biomarker for Ovarian Cancerhttp://otbd.technologypublisher.com/technology/11709Despite advances in cancer therapy, mortality of women with ovarian cancer has remained constant over the last 20 years.  In the US, ~23,000 women are diagnosed with ovarian cancer every year and ~13,000 deaths occur.  Of particular note is that the survival rate is less than 30% for those with Stage III cancer as opposed to 95% for Stage I diagnoses.  Therefore, early detection is crucial to successful recovery.  Currently, none of the existing serum biomarkers; e.g., CA 125 and CA 72-4, are reliable enough for accurate diagnosis of early stage ovarian cancer. Dr Edward Schuchman and his coll...Thu, 10 Jan 2013 11:58:05 GMTtechnology@mssm.eduhttp://otbd.technologypublisher.com/technology/11709